- Oops!Something went wrong.Please try again later.
DGAP-News: APONTIS PHARMA AG / Key word(s): Personnel
APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed CFO
Thomas Zimmermann has around 25 years of experience in responsible positions with a focus on finance in the pharmaceutical industry. Most recently, he worked in Germany and Austria as Finance Director for the Swiss pharmaceutical company Galderma and as a tax advisor syndic. The business graduate (Diplom-Kaufmann) began his professional career at Ernst & Young as a certified public auditor and certified tax advisor and subsequently in the Transaction Advisory Services division.
"With Thomas Zimmermann, we are gaining a proven expert in the pharmaceutical industry and an experienced financial manager in the areas of Finance, Tax, and Controlling as well as Supply Chain and Internal Control. This, together with his extensive network, makes him the ideal candidate for the planned further development of our company. As 'The Single Pill Company', we combine active ingredients in one preparation for a more improved therapy result. This is the approach we are also pursuing with regard to our corporate structures. By bundling management competencies, APONTIS PHARMA is excellently positioned for future growth," says Karlheinz Gast, Chief Executive Officer (CEO) of APONTIS PHARMA AG.
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes, and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia, and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical regions. From here, the Company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.
APONTIS PHARMA Press Contact
CROSS ALLIANCE communication GmbH
16.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
APONTIS PHARMA AG
Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID:
End of News
DGAP News Service